BridgeBio Announces Exclusive License Agreement with
- BridgeBio is eligible to receive up to $905 million, including an upfront payment of $90 million, and up to $815 million in additional milestone payments...
Stay updated with breaking news from Nasdaq Bbio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- BridgeBio is eligible to receive up to $905 million, including an upfront payment of $90 million, and up to $815 million in additional milestone payments...
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) – Investment analysts at SVB Leerink increased their Q1 2022 earnings estimates for shares of BridgeBio Pharma in a research report issued on Tuesday, March 8th. SVB Leerink analyst M. Foroohar now anticipates that the company will post earnings of ($1.11) per share for the quarter, up from […]
Hudson Bay Capital Management LP acquired a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 20,000 shares of the company’s stock, valued at approximately $937,000. A number of other hedge funds have also bought […]
BridgeBio Pharma, Inc. Prices Upsized Offering of $650 Million Convertible Senior Notes January 25, 2021 23:04 ET | Source: BridgeBio Pharma, Inc. BridgeBio Pharma, Inc. Palo Alto, California, UNITED STATES PALO ALTO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $650 million aggregate principal amount of 2.25% convertible senior notes due 2029 (the “notes”) in a private offering (the “offering”) to qualified institutional buy...